

## KEY OPINION LEADER: ONCOLOGY

### DR. TARINI PRASAD SAHOO

MBBS, MD, DM (Oncology)



#### Educational Qualifications:

|                                                     |                                       |
|-----------------------------------------------------|---------------------------------------|
| DM (Medical Oncology)                               | Kidwai Memorial Institute of Oncology |
| MD (Doctor of Medicine)                             | S.C.B. Medical College, Cuttack       |
| Bachelor of Medicine and Bachelor of Surgery (MBBS) | S.C.B. Medical College, Cuttack       |

#### Experience: >25 years

- Department of Medical Oncology at Indraprastha Apollo Hospital, New Delhi from January 2002 - September 2002.
- Department of Medical Oncology of Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal as Consultant
- Head and Director of the Department of Cancer, at Chirayu Medical College and Hospital
- Director & Medical Oncologist at Silverline Hospital, Bhopal
- Editorial board- In the editorial board of Indian breast cancer resource
- Editorial board member of –
  - Indian journal of cancer
  - Cancer Research, Statistics and Treatment
  - Indian Journal of Medical and Paediatric Oncology
  - South Asian Journal of cancer

#### Publications/Presentations:

- Sino-oral zygomycosis due to *Absidia corymbifera* in a patient with acute leukemia. Mohammed S, Sahoo TP, Jayshree RS, Bapsy PP, Hema S. Med Mycol. 2004 Oct;42(5):475-8.
- Recent advances in the management of metastatic breast cancer PP Bapsy, TP Sahoo Indian Journal of medical and paediatric oncology, 2004, 25(2):19-27
- Waldenstrom's macroglobulinemia. Singhal N, Bapsy PP, Babu KG, Sahoo TP. J Assoc Physicians India. 2004 Dec;52:981-5. Review.
- Unusual metastasis in colorectal cancer. Attili VS, Rama Chandra C, Dadhich HK, Sahoo TP, Anupama G, Bapsy PP. Indian J Cancer. 2006 Apr-Jun;43(2):93-5.
- A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Curtis CE, Grand FH, Waghorn K, Sahoo TP, George J, Cross NC. Leukemia. 2007 Aug;21(8):1839-41. Epub 2007 May 17

- Acute toxoplasmosis in nonstem cell transplant patients with haematological malignancies: a study from a regional cancer institute in South India. Adurthi S, Sahoo T, Chakka K, Radhika B, Appaji L, Bapsy P, Ramesh C, Jayshree R. *Hematol Oncol*. 2008 Dec;26(4):229-33
- Cutaneous Metastasis in a Case of Carcinoma Stomach 1Dr V Satya Suresh Attili, 1Dr PP Bapsy, 1Dr Lokanatha D, 2Dr Rajashekar H, 2Dr. Ramachandra C. *Austral - Asian Journal of Cancer* ISSN-0972-2556, Vol. 7, No.4, October 2008
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren- Grul C, Gridelli C. *Lancet Oncol*. 2012 Mar;13(3):247-55.
- Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. *N Engl J Med*. 2012 Feb 16;366(7):601-9.
- Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. *Cancer*. 2012 Oct 1;118(19):4694-705.
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L. *Eur J Cancer*. 2013 Jan;49(2):312-22.
- PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren- Grul C, Gridelli C. *J Clin Oncol*. 2013 Aug 10;31(23):2895-902.
- Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with nonsquamous non-small cell lung cancer. Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, Wang J, Kim HK, Sahoo TP, Digumarti R, Wang X, Altug S, Orlando M. *Eur J Cancer*. 2013 Oct;49(15):3111-21.
- ICON 2013: practical consensus recommendations for hormone receptor-positive Her2- negative advanced or metastatic breastcancer. Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda R, Pavitrana K, Mehta A, Parmar V, Desai S, Nair R, Doval D. *Indian J Cancer*. 2014 Jan-Mar;51(1):73-9.
- Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C. *J Thorac Oncol*. 2014 Feb;9(2):205-13.
- Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing Kumar Prabhash . Suresh H. Advani . Ullas Batra . Bivas Biswas . Anuradha Chougule. Mithua Ghosh . Vamshi Krishna Muddu . T. P. Sahoo . Ashok K. Vaid *Adv Ther* <https://doi.org/10.1007/s12325-019-00903-y>
- Advanced therapeutic options and importance of rebiopsy in epidermal growth factor receptor – kinase inhibitor progressed non small cell carcinoma patients : An expert opinion Suresh H. Advani, Hemant Malhotra, Raju titus Chacko, Maheboob Basade, Pavithran Keechilat, PN Mahapatra, Chanchal Goswami, T.P.Sahoo, Chirag Shah *Indian Journal of cancer*.2017,54 (5), 31-36
- Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian prospective Sudeep Gupta, chatterjee Sanjoy, Nigade jagdish, T P Sahoo, et al *Indian Journal of Medical and Paediatric oncology* 39 (3), 368 , 2018

- Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant) M.Singhal, T.P.Sahoo, Purvish M. Parikh South Asian J cancer.2018 Apr-Jun; 7(2):151-155
- Special considerations for consent in immuno-oncology - Medic LAWgic recommendations Purvish M. Parikh1 \*, Karishma Jhaveri2 , Ankur Bahl3 , Vineet Talwar , Pritish Gandhi5 ,Randeep Singh6 , Sudeep Shreshta7 , TP Sahoo International Journal of Molecular & Immuno Oncology • 2019 • 4(1)
- Treating EGFR-positive advanced cancer lung – Did the water just get muddier? Tarini Prasad Sahoo Cancer Research, Statistics, and Treatment / Volume 2 / Issue 2 / July-Dec

### **Clinical Trial Experience:**

As Principal Investigator in 39 multicentric studies.